Ubs Group Ag Plus Therapeutics, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.27 - $0.48 $5,127 - $9,115	-18,990 Reduced 99.93%	13 $0
Q4 2022 Feb 08, 2023	BUY	$0.3 - $8.4 $838 - $23,478	2,795 Added 17.24%	19,003 $6,000
Q3 2022 Nov 10, 2022	BUY	$0.48 - $7.5 $1,209 - $18,900	2,520 Added 18.41%	16,208 $7,000
Q2 2022 Aug 10, 2022	BUY	$0.46 - $1.02 $6,290 - $13,948	13,675 Added 105192.31%	13,688 $7,000
Q3 2020 Nov 12, 2020	BUY	$2.11 - $3.17 $27 - $41	13 New	13 $0
Q4 2019 Feb 14, 2020	SELL	$1.99 - $3.23 $3 - $6	-2 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.3 - $19.25 $6 - $38	2 New	2 $0

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $36.3M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.